| All Releases |
 |
Eurand to Participate in Upcoming Investor Conferences
Sep 2, 2010
|
10.7 KB |
|
| |
PHILADELPHIA, PA, Sep 02, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, is scheduled to participate in the following upcoming investor conferences:
Event: Stifel Nicolaus Healthcare Conference
Date: Thursday, September 16, 2010
Time: 10:20 a.m. E...
|
|
Eurand Reports Recent Highlights and Second Quarter 2010 Financial Results
Aug 6, 2010
|
25.8 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Aug 06, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX)
Recent Highlights:
-- Second quarter revenues grew 8% to EUR 32.9 million ($40.5 million)
versus second quarter 2009.
-- Product sales rose 22% to EUR 29.4 million ($36.2 million) in the
second quarter of 2010 compared ...
|
|
Eurand to Present at Bank of America Merrill Lynch Specialty Pharmaceuticals Conference
Jul 29, 2010
|
9.9 KB |
|
| |
PHILADELPHIA, PA, Jul 29, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that John Fraher, Chief Commercial Officer, is scheduled to present at the Bank of America Merrill Lynch Specialty Pharmaceuticals Conference. Details are as follows:
Date: Thursday, A...
|
|
Eurand Announces Conference Call on Second Quarter 2010 Financial Results
Jul 19, 2010
|
11.0 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Jul 19, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, will host a conference call on Friday, August 6, 2010 at 8:30 a.m. ET to discuss its second quarter 2010 financial results. The conference call will be hosted by Gearoid Faherty, Chairman and Chief ...
|
|
Eurand Announces Data on Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEPs to FDA-Approved ZENPEP(R)
Jun 17, 2010
|
16.1 KB |
|
| |
YARDLEY, PA, Jun 17, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V. (NASDAQ: EURX), today announced additional data from a post-hoc analysis of a Phase III clinical trial with ZENPEP(R) (pancrelipase) Delayed-Release Capsules, an FDA-approved pancreatic ...
|
|
Eurand Names Former Solvay Executive Jean-Louis Anspach President of U.S. Pharmaceuticals Business
Jun 16, 2010
|
13.4 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Jun 16, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced the appointment of Jean-Louis Anspach as President, Eurand Pharmaceuticals, Inc. (EPI). Anspach is a 25-year veteran of the specialty pharmaceutical and chemical industries and was m...
|
|
Eurand Reports Recent Highlights and First Quarter 2010 Financial Results
May 14, 2010
|
22.4 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, May 14, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX)
Recent Highlights:
-- First quarter 2010 revenues grew to EUR 31.1 million ($42.0 million), an increase of 7%, or 11% in constant currency, from the first quarter of 2009.
-- Net income for the three months ended March 31, 2010 wa...
|
|
Eurand Announces National Title Sponsorship of New Cystic Fibrosis Foundation Fundraiser
May 3, 2010
|
16.4 KB |
|
| |
BETHESDA, MD, May 03, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, has announced its national title sponsorship of the inaugural ZENPEP(R) CF Cycle for Life tour series, a new fundraising event of the Cystic Fibrosis Foundation. The announcement was made at the CF Foundation's n...
|
|
Eurand to Present at Bank of America Merrill Lynch Health Care Conference
Apr 27, 2010
|
10.0 KB |
|
| |
PHILADELPHIA, PA, Apr 27, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that John Fraher, Chief Commercial Officer, is scheduled to present at the Bank of America Merrill Lynch Health Care Conference. Details are as follows:
Date: Tuesday, May 11, 2010
...
|
|
Eurand to Present at Deutsche Bank Securities Health Care Conference
Apr 20, 2010
|
10.0 KB |
|
| |
PHILADELPHIA, PA, Apr 20, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that Gearoid Faherty, Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank Securities 35th Annual Health Care Conference. Details are as follows:
Date: Tue...
|
|
Eurand Announces Conference Call on First Quarter 2010 Financial Results
Apr 14, 2010
|
11.3 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Apr 14, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, will host a conference call on Friday, May 14, 2010 at 8:30 a.m. ET to discuss its first quarter 2010 financial results. The conference call will be hosted by Gearoid Faherty, Chairman and Chief Exe...
|
|
Eurand to Present at Barclays Capital Global Healthcare Conference
Mar 10, 2010
|
9.9 KB |
|
| |
PHILADELPHIA, PA, Mar 10, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that it is scheduled to present at the upcoming Barclays Capital 2010 Global Healthcare Conference. Gearoid Faherty, Eurand's Chairman and Chief Executive Officer, will be presenting.
...
|
|
Eurand Reports Recent Developments and Fourth Quarter and Full-Year 2009 Financial Results
Mar 4, 2010
|
26.2 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Mar 04, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX)
Recent Developments:
-- Fourth quarter 2009 revenues were EUR 30.3 million ($43.4 million), up 18%, or 28% in constant currency, from the fourth quarter of 2008.
-- Full-year revenues in 2009 grew to a record EUR 120.6 million ($1...
|
|
Eurand to Present at Cowen Health Care Conference
Feb 24, 2010
|
9.9 KB |
|
| |
PHILADELPHIA, PA, Feb 24, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that it is scheduled to present at the upcoming Cowen Health Care Conference. John Fraher, Eurand's Chief Commercial Officer, will be presenting.
Event: Cowen Health Care Conference
Dat...
|
|
Eurand Issued U.S. Patent for ZENPEP(R) (pancrelipase) Delayed-Release Capsules
Feb 16, 2010
|
11.4 KB |
|
| |
PHILADELPHIA, PA, Feb 16, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today the grant of U.S. Patent No. 7,658,918, titled "STABLE DIGESTIVE ENZYME COMPOSITIONS," by the United States Patent and Trademark Office (USPTO). The patent will provide Eurand with coverage un...
|
|
Eurand Announces Conference Call on Fourth Quarter and Full-Year 2009 Financial Results
Feb 4, 2010
|
11.1 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Feb 04, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, will host a conference call on Thursday, March 4, 2010 at 8:30 a.m. ET to discuss its fourth quarter and full-year 2009 financial results. The conference call will be hosted by Gearoid Faherty, Chai...
|
|
Eurand to Present at Deutsche Bank Securities Small- and Mid-Cap Conference
Jan 27, 2010
|
10.1 KB |
|
| |
PHILADELPHIA, PA, Jan 27, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that it is scheduled to present at the upcoming Deutsche Bank Securities Small- and Mid-Cap Conference. Presenting will be Bill Newbould, Eurand's Vice President, Investor Relations.
Eve...
|
|
Eurand Launches ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules
Nov 30, 2009
|
20.1 KB |
|
| |
PHILADELPHIA, PA, Nov 30, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced the commercial availability of ZENPEP(TM) (pancrelipase) Delayed-Release Capsules, a pancreatic enzyme product (PEP) indicated for the treatment of exocrine pancreatic insufficiency (EPI) due ...
|
|
Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients With Exocrine Pancreatic Insufficiency
Nov 13, 2009
|
15.8 KB |
|
| |
PHILADELPHIA, PA, Nov 13, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced data from a Phase II/III clinical study demonstrating that ZENPEP(TM) (pancrelipase) Delayed-Release Capsules significantly improves fat absorption in patients with exocrine pancreatic insuffi...
|
|
Eurand Reports Key Achievements and Strong Revenue Growth for Third Quarter 2009
Nov 5, 2009
|
25.7 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Nov 05, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX)
Key Achievements:
-- Received U.S. Food and Drug Administration (FDA) approval for lead
proprietary product ZENPEP(TM) (pancrelipase) Delayed-Release Capsules, a
pancreatic enzyme product (PEP) for the treatment of exocri...
|
|
|
